Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Comparison of Expression Levels of Mir-29B-3P and Mir-326 in T Helper-1 and T Helper-17 Cells Isolated From Responsive and Non-Responsive Relapsing-Remitting Multiple Sclerosis Patients Treated With Interferon-Beta Publisher Pubmed



Karimi L1 ; Eskandari N1 ; Shaygannejad V2 ; Zare N3 ; Andalib A1 ; Khanahmad H4 ; Mirmosayyeb O2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Iranian Journal of Allergy, Asthma and Immunology Published:2020


Abstract

T helper type 1 (Th1) and Th17 Cells with distinct cytokine profiles including interferon-gamma (IFN-γ) and interleukin 17 (IL-17) have a pivotal role in neuroinflammation and myelin destruction in the central nervous system (CNS) in MS. MicroRNA-29b (MiR-29b) and miR-326 contribute to regulating Th1 and Th17 differentiation and altered expression of the miRNAs could be associated with response to treatment in multiple sclerosis (MS). Therefore, our study aimed to evaluate the percentage of Th1 and Th17 and determining the expression levels of miR-29b-3p and miR-326 in these lymphocyte subpopulations between responsive and non-responsive to interferon beta (IFN-β) therapy in relapsing-remitting multiple sclerosis (RRMS) patients. The present study was performed on 40 RRMS patients following treatment with IFN-β. The percentage of Th1 cells and Th17 cells were determined by flow cytometry in responsive and non-responsive patients. The expression levels of miR-29b-3p and miR-326 were assessed in Th1 and Th17 cells by quantitative polymerase chain reaction (PCR). Enzyme-linked immunosorbent assay (ELISA) was applied to evaluate the plasma levels of IFN-γ and IL-17A. No significant difference was observed in the percentage of Th1 and Th17 cells as well as the expression levels of miR-29b-3p and miR-326 (in Th1 and Th17, respectively) in treated patients. Also, we did not find any significant difference in IFN-γ and IL-17A plasma concentration between responsive or non-responsive to IFN-β therapy in patients with RRMS. IFN-β may regulate other miRNAs in Th1 and Th17 cells than miR29b-3p and miR-326 in MS patients. Copyright © August 2020, Iran J Allergy Asthma Immunol. All rights reserved.
Related Docs
View other Related Docs
1. The Effect of Interferon-Beta Therapy on T-Helper 17/Mir-326 and T-Helper 1/Mir-29B-3P Axis in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2022)
2. Comparison of the Expression of Mir-326 Between Interferon Beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis, Cell Journal (2020)
3. Microrna-29B Variants and Mxa Expression Change During Interferon Beta Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2019)
4. Micrornas: Key Modulators of Disease-Modifying Therapies in Multiple Sclerosis : Pancreatic Cancer Is One of the Lethal Malignant Tumours in the World.In This Study, We Investigated the Car T-Cell Therapy of Pancreatic Cancer, International Reviews of Immunology (2020)
5. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)
6. Mir-326 and Mir-26A, Two Potential Markers for Diagnosis of Relapse and Remission Phases in Patient With Relapsing-Remitting Multiple Sclerosis, Gene (2014)
7. The Role of Micrornas Involved in the Disorder of Blood–Brain Barrier in the Pathogenesis of Multiple Sclerosis, Frontiers in Immunology (2023)
8. Mir-145 and Mir20a-5P Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients, Journal of Molecular Neuroscience (2017)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (47)
Vahid Shaygannejad (34)
Other Related Docs
9. The Effect of Beta Interferon on the Expression of Mir-145 in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2016)
10. Upregulation of Cd4+ T-Cell Derived Mir-223 in the Relapsing Phase of Multiple Sclerosis Patients, Cell Journal (2016)
11. Significant Immunomodulatory and Hepatoprotective Impacts of Silymarin in Ms Patients: A Double-Blind Placebo-Controlled Clinical Trial, International Immunopharmacology (2021)
12. Mir-504 Expression Level Is Increased in Multiple Sclerosis Patients Responder to Interferon-Beta, Journal of Neuroimmunology (2020)
13. Connection of Mir-185 and Mir-320A Expression Levels With Response to Interferon-Beta in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
14. Joint Application of Magnetic Resonance Imaging and Biochemical Biomarkers in Diagnosis of Multiple Sclerosis, Current Medicinal Chemistry (2020)
15. Evaluation of the Expressed Mir‑129 and Mir‑549A in Patients With Multiple Sclerosis, Advanced Biomedical Research (2021)
16. Lncrnas Associated With Multiple Sclerosis Expressed in the Th1 Cell Lineage, Journal of Cellular Physiology (2019)
17. The Role of Cobalamin on Interleukin 10, Osteopontin, and Related Micrornas in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2022)
18. Analysis of the Expression of Mir-34A, Mir-199A, Mir-30C and Mir-19A in Peripheral Blood Cd4+T Lymphocytes of Relapsing-Remitting Multiple Sclerosis Patients, Gene (2018)
19. Il-23 Plasma Level Measurement in Relapsing Remitting Multiple Sclerosis (Rrms) Patients Compared to Healthy Subjects, Immunological Investigations (2015)
20. Microrna-92A Drives Th1 Responses in the Experimental Autoimmune Encephalomyelitis, Inflammation (2019)
21. Transplantation of Human Adipose-Derived Stem Cells Overexpressing Lif/Ifn-Β Promotes Recovery in Experimental Autoimmune Encephalomyelitis (Eae), Scientific Reports (2022)
22. Mir-141 and Mir-200A, Revelation of New Possible Players in Modulation of Th17/Treg Differentiation and Pathogenesis of Multiple Sclerosis, PLoS ONE (2015)
23. Serum Level of Interleukin 36 in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2018)
24. Study of the Correlation Between Mir-106A, Mir-125B, and Mir-330 on Multiple Sclerosis Patients by Targeting Tnfsf4 and Sp1 in Nf-Κb/Tnf-Α Pathway: A Case-Control Study, Cell Journal (2022)
25. Interleukin-33 Plasma Levels in Patients With Relapsing-Remitting Multiple Sclerosis, Biomolecular Concepts (2017)
26. An Integrated Bioinformatics Analysis of the Potential Regulatory Effects of Mir-21 on T-Cell Related Target Genes in Multiple Sclerosis, Avicenna Journal of Medical Biotechnology (2021)
27. Effect of High Dose Vitamin D Intake on Interleukin-17 Levels in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Neuroimmunology (2015)
28. Evaluation of Plasma Soluble Cd137 Level in Relapsing-Remitting Multiple Sclerosis Patients in Comparison With Healthy Controls in Isfahan Province, Iran, Neurology Asia (2020)
29. Expression and Clinical Significance of Il7r, Nfatc2, and Rnf213 in Familial and Sporadic Multiple Sclerosis, Scientific Reports (2021)
30. Il-27 Plasma Level in Relapsing Remitting Multiple Sclerosis Subjects: The Double-Faced Cytokine, Journal of Immunoassay and Immunochemistry (2016)
31. Correlation of Midkine Serum Level With Pro- and Anti-Inflamatory Cytokines in Multiple Sclerosis, Iranian Journal of Immunology (2014)
32. Potential Biomarker and Therapeutic Lncrnas in Multiple Sclerosis Through Targeting Memory B Cells, NeuroMolecular Medicine (2020)
33. Interdependency of Ninj2 Gene Expression and Polymorphism With Susceptibility and Response to Interferon Beta in Patients With Multiple Sclerosis, International Journal of Neuroscience (2024)
34. Genetic Variation in Intergenic and Exonic Mirna Sequence and Risk of Multiple Sclerosis in the Isfahan Patients, Iranian Journal of Allergy, Asthma and Immunology (2018)
35. Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients, Inflammation (2022)
36. Increased Serum Level of Il-37 in Patients With Multiple Sclerosis and Neuromyelitis Optica, Acta Neurologica Belgica (2015)
37. Apamin Administration Impact on Mir-219 and Mir-155-3P Expression in Cuprizone Induced Multiple Sclerosis Model, Molecular Biology Reports (2020)
38. The Comparative Analysis of Serum Levels of Midkine in Patients With Multiple Sclerosis and Control Group, Journal of Isfahan Medical School (2013)
39. Decreased Serum Levels of Interleukin-35 Among Multiple Sclerosis Patients May Be Related to Disease Progression, Journal of Biological Regulators and Homeostatic Agents (2018)
40. High-Resolution Melting Curve Analysis of Polymorphisms Within Cd58, Cd226, Hla-G Genes and Association With Multiple Sclerosis Susceptibility in a Subset of Iranian Population: A Case–Control Study, Acta Neurologica Belgica (2020)
41. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
42. Biased Treg/Th17 Balance Away From Regulatory Toward Inflammatory Phenotype in Relapsed Multiple Sclerosis and Its Correlation With Severity of Symptoms, Journal of Neuroimmunology (2013)
43. The Effect of Plasma Exchange on the Expression of Foxp3 and Rorc2 in Relapsed Multiple Sclerosis Patients, Iranian Journal of Immunology (2015)
44. Semaphorin-3A As an Immune Modulator Is Suppressed by Microrna-145-5P, Cell Journal (2018)
45. First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis, Neurotherapeutics (2025)
46. Revisiting the Antiviral Theory to Explain Interferon-Beta's Effectiveness for Relapsing Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
47. Upregulation of Mtor, Rps6kb1, and Eif4ebp1 in the Whole Blood Samples of Iranian Patients With Multiple Sclerosis Compared to Healthy Controls, Metabolic Brain Disease (2020)
48. Research Paper: The Association Between Salt and Potassium Intake With Multiple Sclerosis, Caspian Journal of Neurological Sciences (2019)
49. The Frequencies of Peripheral Blood Cd5+Cd19+ B Cells, Cd3−Cd16+Cd56+ Nk, and Cd3+Cd56+ Nkt Cells and Serum Interleukin-10 in Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder, Allergy, Asthma and Clinical Immunology (2022)
50. Multiple Sclerosis: Clinical Features, Pathophysiology, Neuroimaging and Future Therapies, Future Neurology (2009)